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It has been previously shown that antibiotics given before hospitalization significantly reduce the proportion of 
positive blood cultures in community-acquired pneumonia (CAP). The aim of this prospective study was to compare 
the utility and cost-benefits of blood cultures in patients, hospitalized for moderate CAP, who had or had not 
received antibiotic therapy prior to admission. 
During 1 year, 53 patients were included and separated into two groups: group 1 patients had not received 
antibiotic treatment prior to admission (n=30), whereas group 2 patients had been treated with antibiotics (n=23). 
Within the first 48 hours, a set of blood cultures was collected if the body temperature was higher than 38.K or in 
the case of shaking chills. 
A total of 136 blood cultures was collected; 74 in group 1 and 62 in group 2. Bacteraemia was significantly more 
frequent in group 1 than in group 2, 5130 patients vs. O/23, respectively (PcO.05). The cost of negative blood cultures 
was valued at 13,939.2 FF in group 1 and 13,164.8 FF in group 2, respectively 464.6 & 244.3 FF and 
569.3 f 233.4 FF per patient (n.s.). Moreover, blood cultures were the method of diagnosis in only one of the five 
patients with bacteraemia and in no case did a positive blood-culture result influence the initial therapeutic regime. 
Thus, our results suggest a reduced clinical utility and cost-benefit of blood cultures in patients hospitalized for 
moderate CAP who have received an antibiotic treatment prior to admission. 
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Introduction 
In patients hospitalized for community-acquired pneumo- 
nia (CAP), bacteraemia occurs in 0.5-14% (1,2) with a low 
sensitivity of blood cultures in such cases. In 1993, the 
guidelines of the American Thoracic Society recommended 
that hospitalized patients with CAP should have two sets of 
blood cultures collected (3). However, Chalasani et al. have 
recently suggested that blood cultures may have a question- 
able cost-effectiveness (4). Indeed, it has been previously 
shown that antibiotics given before admission can signifi- 
cantly reduce the proportion of positive blood cultures in 
patients with CAP (5,6). From all these results, it would be 
conceivable to assume that blood cultures are of limited 
value especially in patients that have received an antibiotic 
treatment prescribed before admission. Thus, we conducted 
a prospective study in patients hospitalized for moderate 
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CAP to assess the impact of such antibiotic treatment on 
bacteraemia. We report here a cost-benefit analysis, taking 
into account the relationships that we observed between 
blood cultures and antibiotic treatment given before 
hospitalization. 
Methods 
PATIENTS 
From 1 March 1994 to 28 February 1995, all patients over 
15 years of age hospitalized in the respiratory unit of our 
hospital for moderate CAP were included in a prospective 
study. Pneumonia was defined as any acute septic episode 
with respiratory symptoms and a new or progressive infil- 
trate on chest X-rays. Community-acquired infection was 
defined as an infection occurring before or within 48 h after 
admission in patients that had not been hospitalized during 
the preceding 2 weeks. Moderate pneumonia corresponded 
to an infection requiring hospitalization in a respiratory 
unit but not in an intensive care unit. Patients with a clinical 
history suggestive of aspiration, a severe pneumonia requir- 
ing an intensive care unit, an immunosuppressive illness or 
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who were being treated with immunosuppressive drugs 
were excluded from the study. In all patients, we looked for 
an antibiotic treatment prescribed before hospitalization 
and we recorded the type of antibiotics, the dosage and the 
duration of therapy. 
MICROBIOLOGICAL METHODS 
In each patient, a bronchial sample was taken during the 
12 h following admission and before the onset of antibiotic 
therapy. A sputum sample was obtained when a sputum 
could be produced spontaneously. In the other patients, a 
sample was obtained via a fibre-optic bronchoscope: a 
bronchial aspiration or a minimal bronchial washing [instil- 
lation (50 ml) and aspiration of a physiological solution] 
was performed in segmental bronchi corresponding to the 
infiltrate on chest X-rays. After Gram staining, each 
bronchial sample was cultured on 5% horse’s blood and 
chocolate agars to obtain a quantitative identification. 
Within 48 h of hospital admission, blood cultures were 
collected (before or after the onset of hospital antibiotic 
treatment) only if the body temperature was higher than 
38.K or in cases of shaking chills. Blood (10 ml per set) 
was injected into two culture bottles (one aerobic and the 
other anaerobic) that were transferred to the microbiology 
laboratory for incubation in a Bactec NR 660 (Becton 
Dickinson, MD, U.S.A.) and processing. In culture bottles 
giving a positive growth-index indication, Gram staining 
was initially performed and then two 5% horse blood agars 
were seeded aerobically and anaerobically. Moreover, 
according to the results of the Gram stain, blood specimens 
could be cultured on chocolate and BCP agars. 
Serologies against atypical germs and viruses were 
obtained within 24 h of admission and 15 days later if 
possible. Tests for pneumococcal antigens were performed 
on serum and urine. 
DIAGNOSTIC DEFINITIONS 
The bronchial samples were considered of good quality if 
the Gram stain showed fewer than 10 squamous cells and 
more than 25 leukocytes per low-power field. The micro- 
organism was considered to be the aetiological agent when 
it was isolated from the sputum sample, bronchial aspira- 
tion or minimal bronchial washing at a level equal to or 
higher than 107, lo6 and lo4 colony-forming units 
(CFU) ml - ’ respectively. Serological results were consid- 
ered as diagnostic when there was a four-fold rise in 
antibody titers. Streptococcus pneumoniae was considered 
to be responsible for the infection if pneumococcal antigens 
were found in serum and/or urines. 
Blood cultures were considered to be contaminated if 
they showed only coagulase-negative staphylococci, viri- 
dans streptococci, aerobic or anaerobic Gram-positive 
bacilli. The criteria of true bacteraemia were: two separate 
blood cultures growing the same micro-organism; one 
positive blood culture associated with a bronchial sample 
identifying the same germ; or one blood culture isolating a 
germ and the presence of at least two of the following 
symptoms: respiratory rate over 20 min - ‘, pulse rate over 
90 min - ‘, temperature over 38.5”C or change in the blood 
leukocyte count (7). 
COST OF BLOOD CULTURE 
In 1995, the cost of a negative set of blood cultures was 
211.2 FF. The price rose to 246.4 FF when a germ was 
isolated (contaminated cultures or not). When an antibio- 
gram was performed for a positive blood culture set, the 
cost was 316.8 FF. When more than one blood sample 
grew the same germ, the antibiogram was performed on a 
simple set. 
STATISTICAL ANALYSIS 
Qualitative data from the two groups were compared using 
Fischer’s test. Quantitative data two groups were compared 
using the Student’s t-test. The results were expressed as 
mean & SD. A P-value of CO.05 was considered significant. 
Results 
POPULATION 
During 1 year, 53 patients hospitalized for CAP in our 
department were included in the study: 33 men and 20 
women. Mean age was 55.7 & 18 years (range 1685 years). 
These patients were separated into two groups: group 1 
patients had not received antibiotic treatment prior to 
admission (n= 30), whereas group 2 patients had been 
treated with antibiotics (n=23). The most frequent under- 
lying diseases were chronic obstructive pulmonary disease 
(COPD) (32%), congestive heart failure, and alcoholism 
(13.2%). There was no significative difference in frequency 
of co-existing illnesses between the two groups. 
In group 2 patients, the duration of antibiotic treatment 
before hospitalization was 7.2 * 6.5 days. The most com- 
monly prescribed antibiotics were macrolides (nine 
patients), third-generation cephalosporins (six patients), 
first-generation cephalosporins and ampicillin/amoxycillin 
(five patients), and amoxycillin+clavulanate (four patients). 
AETIOLOGICAL DIAGNOSIS 
A sputum sample was obtained in 13 patients (24.5%) a 
bronchial aspiration in 19 patients (35.8%) and a minimal 
bronchial washing in 21 patients (39.6%). A final diagnosis 
was obtained in 32 patients (60.4%). The most frequently 
identified microbial agent was Streptococcus pneumoniae 
(n= 13) followed by Haemophilus intuenzae (n=9), and 
Gram-negative bacilli (n=5). 
BLOOD CULTURES 
Table 1 shows results from the 136 blood cultures collected 
(74 in group 1 and 62 in group 2). Bacteraemia was 
exclusively observed in group 1 patients (5130 VS. O/23 in 
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TABLE 1. Comparison of blood culture results in two groups of patients. For per patient results, 
values are median f SD 
Group 1 
(n=30) 
Group 2 
(n=23) P-value 
Blood cultures 
Blood cultures per patient 
Patients with bacteraemia 
Positive blood cultures 
Cost of blood cultures (FF) 
Cost of negative blood cultures (FF) 
Cost of negative blood cultures (FF) 
per patient 
74 62 
2.5 f 1.1 2.7 f 1.1 n.s. 
5 0 co.05 
8 0 co.01 
16,262.4 13,164.8 
13,939.2 13,164.8 
464.6 f 244.3 569.3 f 233.4 n.s. 
group 2 patients, PcO.05). In group 1, eight blood cultures our respiratory unit, is small but sufficient at least to give an 
were positive in these five patients (two in three patients and idea of what relevance blood culture may have in such a 
one in two others) whereas in group 2, no blood culture was group; however, without allowing any definite conclusion 
positive (P<O.Ol). The isolated microorganisms were Strep- to be drawn. Moreover, the number of blood cultures was 
tococcus pneumoniue and Haemophilus influenzae (in four not insignificant and the interest of this study lay in the 
and one patients, respectively). In two patients from group comparison between patients who had or had not received 
2, a coagulase-negative staphylococcus was identified. antibiotics before admission. 
The total cost of blood cultures was 29,427.2 FF 
(16,262.4 FF for group 1 and 13,164.8 FF for group 2). The 
cost of negative blood cultures corresponds to the cost that 
could be saved if blood cultures were abandoned. Expressed 
per patient, this cost was higher in group 2 (569.3 & 
233.4 FF) than in group 1 (464.6 f 244.3 FF), but the 
difference was not significant. 
The effective cost of one positive blood culture that could 
be estimated through the ratio of total cost of blood 
cultures divided by the number of positive blood cultures 
was 2032.8 FF for group 1. In fact, to obtain a positive 
culture in this group, eight blood cultures were performed 
and were negative. This ratio could not be evaluated in 
group 2 as no blood culture was positive. 
Only patients with a moderate pneumonia requiring 
hospitalization according to the ATS guidelines were 
included in this study. Indeed, in severe pneumonia, blood 
cultures appear to be more frequently positive than in cases 
of moderate pneumonia. Moreover, bacteraemia is a prog- 
nostic factor associated with mortality (8-10) which shows 
the relevance of blood culture in severe CAP. In this study, 
we also excluded patients with an immunosuppressive ill- 
ness or who were being treated with immunosuppressive 
drugs because it has been previously demonstrated that the 
risk of bacteraemic pneumonia is increased in these patients 
(11,12). 
Furthermore, blood culture was the only microbiological 
method used in assessing diagnosis in only one of the five 
patients with bacteraemia. Finally, the micro-organisms 
isolated from blood cultures were always susceptible to the 
initial antibiotic therapy given during hospitalization and in 
none of these five patients did the microbiological results 
influence the hospital antibiotic treatment. 
Blood cultures were collected in our patients only when 
their temperature was higher than 38.5”C or in cases with 
shaking chills, considered to be clinical predictors for true 
bacteraemia (13). Also, only five out of 53 patients had true 
positive blood cultures (9.4%). This low percentage is in 
agreement with the literature, which reports a frequency 
ranging from 0.5 to 14% in CAP (1,2,5,6,14-18). Moreover, 
in agreement with most studies (4,6,17), we found that 
Streptococcus pneumoniae was the most common bacteria 
found in bacteraemic pneumonia (four of five patients). 
Discussion 
This prospective study was conducted to assess the intlu- 
ence of antibiotic therapy given prior to admission on the 
results and the clinical utility of blood culture. Our results 
showed low cost-effectiveness of this microbiological 
method in patients who had received antibiotic treatment 
before hospitalization. Moreover, this study suggests a poor 
impact of the positive blood culture on prescription of the 
hospital antibiotic treatment. 
Our results show that antibiotic therapy prior to 
hospitalization significantly decreased the frequency of 
bacteraemia in CAP, as previously reported (6,15). This 
could be due to the fact that the antibiotic therapy given 
before admission had been effective, at least partially, 
against Streptococcus pneumoniae, the most frequent patho- 
gen isolated in CAP (2,3,5,6,15-18,19-22). Thus, the use of 
antibiotic treatment prior to hospitalization can be consid- 
ered a criterion for low risk of bacteraemia and this 
conclusion casts doubt on the utility of blood cultures in 
this group of patients. 
Some aspects of this study merit consideration. The 
number of patients, corresponding to 1 year’s admission to 
Only a few papers have addressed the cost of the diag- 
nostic procedures in CAP. In 1995, in a retrospective study 
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of 517 patients with CAP, Chalasani et al. reported $66 
(376.2 FF) spent per patient for blood cultures, which had 
little influence on the therapeutic regimen. However, the 
authors were unable to specify whether there had been prior 
use of an antibiotic at home (4). In our study, the cost of 
blood culture per patient was higher; this could be 
explained by our calculation of cost per set of blood 
cultures and a higher number of sets performed per patient 
in our population than in the study of Chalasani et al. (4). 
Analysis of the cost of blood specimens in our two groups 
showed that the cost of negative blood cultures per patient 
was consistent, particularly in patients who had received 
antibiotic therapy prior to admission, showing the influence 
of this treatment on the cost-benefits of blood culture. 
However, blood culture can enable a specific diagnosis 
with a lower probability of false-positive cultures than with 
bronchial samples. Indeed, even if a high minimal count of 
CFU per millilitre was retained, positive culture results 
from bronchial samples were not unequivocal. Moreover, 
in some centres, particularly on geriatric wards, sputum 
specimens or bronchial samples are rarely obtained and the 
aetiological diagnosis can only be acquired from blood 
cultures. Finally, a positive blood culture result may save 
money by enabling a less broad-spectrum antibiotic treat- 
ment. However, because of the absence of positive cultures 
in group 2, we did not analyse the additional costs of 
antibiotics or other treatments. 
Thus, despite the small numbers, our data confirm the 
reduced clinical usefulness and extremely low cost-benefit 
of blood cultures in patients hospitalized for moderate CAP 
and treated with antibiotics before admission. Blood cul- 
tures are useful in microbiological specific diagnosis and 
decision-making in antibiotic treatment, particularly in 
centres where bronchial samples cannot be obtained. HOW- 
ever, at a time when medical economy is major considera- 
tion, it can be suggested that the use of blood culture could 
be abandoned without deleterious consequences in those 
patients who have received antibiotic therapy prior to 
hospitalization. 
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